ArticleSkin health and disease2023

No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies.

Johannes Griss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.